Kiora Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 12, 2026, disclosing condensed consolidated financial statements and related disclosures for the three and nine months ended September 30, 2026.
Key Highlights
- Cash and cash equivalents: $5,570,640 as of September 30, 2026, down from $8,696,570 at December 31, 2025, according to the filing.
- Short-term investments: $10,716,331 as of September 30, 2026, compared with $8,392,513 at December 31, 2025, per the balance sheet.
- Total assets: $22,374,062 as of September 30, 2026, versus $24,253,300 at December 31, 2025, as reported in the filing.
- Total liabilities: $7,077,903 as of September 30, 2026, down from $8,126,764 at December 31, 2025, the company disclosed.
- Shares outstanding: 4,424,387 shares of common stock as of November 10, 2026, according to the filing's cover page.
- Contingent consideration: $3,082,326 recorded as a non-current liability as of September 30, 2026, per the balance sheet.
Kiora Pharmaceuticals Balance Sheet Position as of September 30, 2026
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), a Delaware-incorporated smaller reporting company headquartered at 169 Saxony Rd., Suite 212, Encinitas, CA 92024, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing covers three and nine month periods ended September 30, 2026, and includes unaudited condensed consolidated financial statements.
According to the balance sheet, total current assets stood at $19,914,089 as of September 30, 2026, compared with $21,748,448 at December 31, 2025. The decline in current assets was driven in part by a reduction in cash and cash equivalents and in collaboration receivables, which fell from $1,522,770 at December 31, 2025 to $636,756 at September 30, 2026, the filing shows. Short-term investments increased over the same period, from $8,392,513 to $10,716,331. The company also reported intangible assets and in-process R&D, net, of $2,063,100 as of both September 30, 2026 and December 31, 2025.
On the liabilities side, the company disclosed that accounts payable declined from $1,060,306 at December 31, 2025 to $209,074 at September 30, 2026. Accrued expenses were $2,147,562 at September 30, 2026 versus $2,406,731 at December 31, 2025. Non-current liabilities included deferred collaboration revenue of $1,250,000 at both dates. The filing noted preferred stock with $0.01 par value across multiple designated series, including 7 shares of Series D issued and outstanding and 420 shares of Series F issued and outstanding at September 30, 2026. The filing contains forward-looking statements that the company described as subject to risks and uncertainties, with no assurance of updating them unless required by federal securities laws.
What Was Disclosed
Kiora Pharmaceuticals filed its September 30, 2026 quarterly report disclosing unaudited condensed consolidated balance sheet data, including total assets of $22,374,062, total liabilities of $7,077,903, and 4,424,387 shares of common stock outstanding as of November 10, 2026.



Please wait processing your request...